全文获取类型
收费全文 | 1329351篇 |
免费 | 114627篇 |
国内免费 | 6350篇 |
专业分类
耳鼻咽喉 | 16684篇 |
儿科学 | 42913篇 |
妇产科学 | 36537篇 |
基础医学 | 182405篇 |
口腔科学 | 36250篇 |
临床医学 | 120072篇 |
内科学 | 276360篇 |
皮肤病学 | 31861篇 |
神经病学 | 109753篇 |
特种医学 | 55492篇 |
外国民族医学 | 274篇 |
外科学 | 209890篇 |
综合类 | 31491篇 |
现状与发展 | 2篇 |
一般理论 | 414篇 |
预防医学 | 105921篇 |
眼科学 | 28015篇 |
药学 | 93465篇 |
5篇 | |
中国医学 | 2153篇 |
肿瘤学 | 70371篇 |
出版年
2018年 | 13377篇 |
2017年 | 10631篇 |
2016年 | 12793篇 |
2015年 | 14302篇 |
2014年 | 19948篇 |
2013年 | 29738篇 |
2012年 | 36242篇 |
2011年 | 38888篇 |
2010年 | 24373篇 |
2009年 | 23905篇 |
2008年 | 36365篇 |
2007年 | 38779篇 |
2006年 | 39907篇 |
2005年 | 38488篇 |
2004年 | 36727篇 |
2003年 | 35784篇 |
2002年 | 33763篇 |
2001年 | 65963篇 |
2000年 | 67749篇 |
1999年 | 56271篇 |
1998年 | 15980篇 |
1997年 | 14204篇 |
1996年 | 15221篇 |
1995年 | 16155篇 |
1994年 | 15040篇 |
1993年 | 14074篇 |
1992年 | 47041篇 |
1991年 | 45738篇 |
1990年 | 43951篇 |
1989年 | 41791篇 |
1988年 | 38725篇 |
1987年 | 38060篇 |
1986年 | 35834篇 |
1985年 | 34620篇 |
1984年 | 26329篇 |
1983年 | 22060篇 |
1982年 | 13809篇 |
1981年 | 12405篇 |
1980年 | 11664篇 |
1979年 | 23505篇 |
1978年 | 17020篇 |
1977年 | 14337篇 |
1976年 | 13139篇 |
1975年 | 13694篇 |
1974年 | 16067篇 |
1973年 | 15380篇 |
1972年 | 14167篇 |
1971年 | 13024篇 |
1970年 | 11863篇 |
1969年 | 11092篇 |
排序方式: 共有10000条查询结果,搜索用时 21 毫秒
41.
42.
43.
Estefany I. Medina-Reyes Carolina Rodríguez-Ibarra Daniel Díaz-Urbina Alejandro Déciga-Alcaraz Normal L. Delgado-Buenrostro Yolanda I. Chirino José Pedraza-Chaverri 《Journal of applied toxicology : JAT》2022,42(8):1411-1419
Food-grade titanium dioxide (E171) is widely used as a food additive, and it is known that after oral consumption, E171 is translocated into the bloodstream reaching the highest titanium level at 6 h. E171 is accumulated in some organs triggering toxicity, but the effects on the blood parameters after oral consumption have been less studied. Recently, evidence shows that oral exposure to E171 induces behavioral signs of anxiety and depression. The relation between blood alterations and psychiatric disorders has been previously demonstrated. However, the oral exposure to E171 effects on alterations in blood parameters and effects linked to alterations in animal behavior has not been explored. In this short communication, we aimed to investigate the effects of E171 on specific blood parameters (hematocrit, hemoglobin, number of erythrocytes, and leukocytes) and anxiety and compulsive-like behavior in males and females orally exposed to ~5 mg/kg for 4 weeks. The results showed that E171 decreased hematocrit and hemoglobin in male but not in female mice while leukocyte and erythrocyte count remained unaltered. Oral consumption of E171 decreased the levels of anxiety-like behavior in females but not in male mice, while compulsive-like behavior was increased in both male and female mice. 相似文献
44.
45.
46.
Sanne C. F. A. Huijberts Robin M. J. M. van Geel Emilie M. J. van Brummelen Frans L. Opdam Serena Marchetti Neeltje Steeghs Saskia Pulleman Bas Thijssen Hilde Rosing Kim Monkhorst Alwin D. R. Huitema Jos H. Beijnen Ren Bernards Jan H. M. Schellens 《Cancer chemotherapy and pharmacology》2020,85(5):917-930
KRAS oncogene mutations cause sustained signaling through the MAPK pathway. Concurrent inhibition of MEK, EGFR, and HER2 resulted in complete inhibition of tumor growth in KRAS-mutant (KRASm) and PIK3CA wild-type tumors, in vitro and in vivo. In this phase I study, patients with advanced KRASm and PIK3CA wild-type colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer, were treated with combined lapatinib and trametinib to assess the recommended phase 2 regimen (RP2R). Patients received escalating doses of continuous or intermittent once daily (QD) orally administered lapatinib and trametinib, starting at 750 mg and 1 mg continuously, respectively. Thirty-four patients (16 CRC, 15 NSCLC, three pancreatic cancers) were enrolled across six dose levels and eight patients experienced dose-limiting toxicities, including grade 3 diarrhea (n = 2), rash (n = 2), nausea (n = 1), multiple grade 2 toxicities (n = 1), and aspartate aminotransferase elevation (n = 1), resulting in the inability to receive 75% of planned doses (n = 2) or treatment delay (n = 2). The RP2R with continuous dosing was 750 mg lapatinib QD plus 1 mg trametinib QD and with intermittent dosing 750 mg lapatinib QD and trametinib 1.5 mg QD 5 days on/2 days off. Regression of target lesions was seen in 6 of the 24 patients evaluable for response, with one confirmed partial response in NSCLC. Pharmacokinetic results were as expected. Lapatinib and trametinib could be combined in an intermittent dosing schedule in patients with manageable toxicity. Preliminary signs of anti-tumor activity in NSCLC have been observed and pharmacodynamic target engagement was demonstrated. 相似文献
47.
Kerryn W. Reding Aaron K. Aragaki Richard K. Cheng Ana Barac Sylvia Wassertheil-Smoller Jessica Chubak Marian C. Limacher W. Gregory Hundley Ralph D'Agostino Jr. Mara Z. Vitolins Theodore M. Brasky Laurel A. Habel Eric J. Chow Rebecca D. Jackson Chu Chen April Morgenroth Wendy E. Barrington Matthew Banegas Matthew Barnhart Rowan T. Chlebowski 《The oncologist》2020,25(8):712-721
48.
49.
50.